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Background: The cellular response to DNA damage requires multiple signaling pathways to guarantee genomic stability.
Results:Vaccinia-related kinase 1 (VRK1) is activated by ionizing radiation and required for formation of 53BP1 foci in response
to DNA damage.
Conclusion: Human VRK1 is an early step in the cellular response to DNA damage induced by ionizing radiation.
Significance: VRK1 forms part of a novel pathway for DNA protection.
Cellular responses to DNA damage require the formation of
protein complexes in a highly organized fashion. The complete
molecular components that participate in the sequential signal-
ing response to DNA damage remain unknown. Here we dem-
onstrate that vaccinia-related kinase 1 (VRK1) in resting cells
plays an important role in the formation of ionizing radiation-
induced foci that assemble on the 53BP1 scaffold protein during
the DNA damage response. The kinase VRK1 is activated by
DNA double strand breaks induced by ionizing radiation (IR)
and specifically phosphorylates 53BP1 in serum-starved cells.
VRK1 knockdown resulted in the defective formation of 53BP1
foci in response to IR both in number and size. This observed
effect on 53BP1 foci is p53- and ataxia-telangiectasia mutated
(ATM)-independent and can be rescued with VRK1 mutants
resistant to siRNA. VRK1 knockdown also prevented the acti-
vating phosphorylation of ATM, CHK2, and DNA-dependent
protein kinase in response to IR. VRK1 activation in response to
DNA damage is a novel and early step in the signaling of mam-
malian DNA damage responses.
When cells encounter stress, such asDNAdamage, they acti-
vate complex signaling networks that regulate their ability to
detect and repair the damage and return to homeostatic equi-
librium. These networks integrate a wide variety of signals from
inside the cell, transduced through protein kinases (1–3), to
ultimately control cell cycle arrest or progression in the case of
dividing cells (4). A major risk of DNA damage is the transmis-
sion of unrepaired DNA lesions to the progeny (5) that are
implicated in aging and cancer (6). In addition to cancer, defec-
tive DNA repair is also associated with neurodegenerative dis-
eases (7). Understandably, most research into DNA damage
responses has been performed in the context of cell division (5).
However, in the human body, most of the cells are in the G0
state and are not dividing at the time of DNA damage. Such
responses are particularly important for resting or quiescent
cells, such as stem cells and neurons. Thus, the initial response
toDNAdamage is an individual cell function that does not have
to be linked to cell division. Francis Crick (8) predicted that
several redundant mechanisms must exist to repair damaged
DNA and maintain genome integrity. Since then, several path-
ways have been identified (1–3).
We hypothesized that cells must rapidly and efficiently sense
these DNA lesions before they divide to avoid transmission to
their progeny. Because nuclear kinases are capable of rapidly
responding to changes in the cell and its environment and inte-
grating diverse stimuli, we suspected that they might be impli-
cated in sensing and triggering downstream signaling that is
needed for proper DNA damage repair. The most common
pathways in the DNA damage response (DDR)3 implicate pro-
tein phosphorylation by different kinases, such as ATM (1),
ATR (2), and DNA-PK (3), which have been mostly studied in
the context of cell division and cell cycle checkpoints (4). In
response to double strand breaks induced by ionizing radiation
(IR), 53BP1 scaffold protein is recruited to IR-induced foci,
constituting an importantmarker formonitoring cellular DDR.
53BP1 foci are intermediate steps in DDR activation (9, 10) and
are known to be regulated by ATM in response to DNA double
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strandbreaks (DSBs) (11) andbyATR in response to replication
stress (12). However, it is also known that the DNA damage
response to DNA DSBs can be ATM-independent (13). This
suggests that there are alternative kinases participating in DDR
induced by ionizing radiation.
DDR signaling induced by different genotoxic agents con-
verge on p53 phosphorylation events (14, 15). Nuclear kinase
vaccinia-related kinase 1 (VRK1), a Ser-Thr kinase, phosphor-
ylates p53 atThr-18 (16–18). This p53 residue is the key residue
controlling the binding of p53 with its negative regulator
Mdm2. Thr-18 phosphorylation increases binding of p53 to
transcriptional cofactors by 3 orders of magnitude (19, 20),
whereas p53 with unphosphorylated Thr-18 preferentially
binds to ubiquitin ligases, such as Mdm2/Hdm2. Thr-18 phos-
phorylation plays a threshold role in p53 responses (17, 21), and
additional p53 phosphorylations contribute to the specificity of
cofactor selection (20). VRK1, which can phosphorylate p53
(16), has been associated with later stages of the DDR andmul-
tiple effectormechanisms (18, 22).HumanVRK1 is required for
entry in the cell cycle (23), and its loss causes a cell cycle arrest
in G0 (23). VRK1 phosphorylates histones and promotes chro-
matin compaction in mitosis (24, 25) as does nucleosomal his-
tone kinase-1 (NHK-1), its Drosophila melanogaster ortholog
(26). VRK1 directly interacts with histones, and its kinase activ-
ity is regulated by these interactions (27). VRK1 also regulates
the proviral DNA preintegration complex of retroviruses (28).
VRK1participation in nucleoprotein complexes can have a dual
role either affecting local chromatin structure or alternatively
reacting to changes in chromatin, which suggests that VRK1
might function as part of chromatin signaling pathways (29–
31). But a kinase responding to changes in chromatin structure
should also mediate responses aiming to signal or repair dam-
aged DNA, which also requires chromatin remodeling. VRK1
can thus be a novel protein involved in these processes. This
regulatory function is a very suitable role for a kinase that
appeared late in evolution, such as VRK1 (32), whose role is
more likely to be the coordination of preexisting pathways in
higher and more complex organisms. Here we identify a novel
role for VRK1 in responding to DSBs that directly connects the
signal of damaged DNA to the DDRmediator protein 53BP1 in
a p53- and ATM-independent mechanism.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture—A549, H1299, MCF7, GM9607,
HT144, and HEK293T cells were from ATCC. Cells were
grown as monolayers in DMEM supplemented with 10% fetal
calf serum, 2 mM glutamine, 50 g/ml penicillin, and 50 g/ml
streptomycin. Cells were detached with trypsin-EDTA solu-
tion. All cell culture reagents were from Invitrogen.
Plasmids—VRK1 protein was expressed in bacteria from
clone pGEX4T-GST-VRK1 (16) or pET23-VRK1-his. GST-53-
BP1 fragments in pGEX were from J. Chen (33). GST-p53(1–
85) was described previously (16). GST fusion proteins were
purified using glutathione-Sepharose 4B (GE Healthcare) and
eluted with reduced glutathione. His-tagged proteins were
purified using Talon resin (Clontech). Mammalian expression
plasmid p-CEFL-HA-VRK1 was described previously (17).
Plasmid p-CEFL-HA-VRK1(R391/R393/V394), resistant to
si-VRK1–01, was generated by introducing three silent nucle-
otide changes at the third codon position in residues Arg-391,
Arg-393, and Val-394 by site-directed mutagenesis with the
QuikChangemutagenesis kit from Stratagene (San Diego, CA).
Plasmid p-HA-53BP1 full length was fromT. Halazonetis (9) as
well as plasmids pCMV-FLAG-CHK2 and pCMV-FLAG-
CHK2(A347). Plasmids pBJ1-HA-ATM wild type and kinase-
dead were from J. R. Nevins (34). Plasmids pcDNA3-FLAG-
ATR wild type and kinase-dead (D2475A) were from R. T.
Abraham (35).
Cell Transfections—In experiments in which plasmid con-
structs were transiently transfected, cells were in exponential
growth phase. Twenty-four hours before transfection, cells
were plated in P100 dishes at 60–70% confluence at the time of
transfection. Plasmid DNAs formammalian transfections were
prepared using the JETStar endotoxin-free maxiprep kit
(Genomed GmbH). The specific plasmids used are indicated in
the individual experiments. Transfections of the cell lines used
in this report have already been reported (25, 36).
RNA Interference—Specific silencing of VRK1 was per-
formed using two different siRNAs: siVRK1-01 (siV1-01) and
siVRK1-02 (siV1-02). Both were designed with the SMART-
selection algorithm (Dharmacon RNAi Technologies) and
obtained from Dharmacon RNAi Technologies. The sequence
targets of the two VRK1 siRNA oligos were as follows:
siVRK1-01, GAAAGAGAGTCCAGAAGTA; and siVRK1-02,
CAAGGAACCTGGTGTTGAA. As a negative control,
indicated as siCt in experiments, the ON-TARGETplus
siCONTROL Non-targeting siRNA from Dharmacon RNAi
Technologies was used. The efficiency of RNAi transfection
was determined with siGLO RISC-free siRNA (Dharmacon
RNAi Technologies) labeled with a red fluorochrome.
Cells were transfected with the indicated siRNA at a concen-
tration of 20 nM using Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. After transfec-
tion, cells were processed for specific experiments at the times
indicated. Experiments were performed as reported previously
(18, 23, 37). For rescue experiments, cells were transfected with
the indicated siRNA using Lipofectamine 2000 reagent. After
36 h, cells were retransfected with plasmids using Lipo-
fectamine at a 1:5 ratio (g of DNA:l of Lipofectamine). Tar-
geted protein and plasmid expression was analyzed 36 h after
the second transfection.
Kinase Assays—In vitro kinase activity of VRK1 was analyzed
using recombinant proteins expressed in Escherichia coli BL21
strain in a buffer containing 20 mM Tris-HCl, pH 7.5, 5 mM
MgCl2, 0.5 mMDTT, 150 mM KCl, 5 MATP, and 5 Ci of (0.1
M) [-32P]ATP (PerkinElmer Life Sciences) in a final volume
of 30 l. As substrates, recombinant proteins also were used as
indicated in each individual assay. Reactions were performed at
30 °C for 30 min (38) with mild shaking in a Thermomixer
Compact (Eppendorf). Endogenous VRK1 assays were per-
formed under the same conditions using the protein immuno-
precipitated from the cell line indicated in the experiment in a
final volume of 65 l. For kinase assays, VRK1 was routinely
immunoprecipitated with 1F6 monoclonal antibody (39).
ATMandATR kinase assays were performed in a buffer con-
taining 10 mM Hepes, pH 7.5, 10 mM MgCl2, 10 mM MnCl2, 50
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mM NaCl, 1 mM DTT, 50 M ATP, and 5 Ci of (0.1 M)
[-32P]ATP (33). The CHK2 kinase assay was performed in
buffer containing 50 mM Hepes, pH 8.0, 10 mM MgCl2, 2.5 mM
EDTA, 1 mM DTT, 10 M ATP, and 5 Ci of (0.1 M)
[-32P]ATP (40).
Reactions were stopped by adding loading buffer (62.5 mM
Tris-HCl, pH 6.8, 10% glycerol, 2.3% SDS, 0.1% bromphenol
blue, and 5% -mercaptoethanol) and heating at 100 °C for 5
min. Proteins were separated by SDS-PAGE (25). Gels were
either stained with Coomassie Blue or transferred to a PDVF
membrane (Immobilon-P, Millipore). Radioactivity was
detected by exposure to x-ray film (Fujifilm) or by Molecular
Imager FX (Bio-Rad). Control bands were detected with Coo-
massie Blue, Ponceau staining, or Western blot with a specific
antibody as indicated in the individual experiment. Detection
of specific phosphorylation in specific residues was performed
byWestern blot with the indicated phosphospecific antibodies
of the corresponding protein.
Antibodies—Human VRK1 was detected by immunofluores-
cence and in Western blots with monoclonal 1B5 (39) or poly-
clonal anti-VRK1 from Sigma (HPA000660). Endogenous
VRK1was routinely immunoprecipitated with 1F6monoclonal
antibody (39). 1B5 and anti-VRK1 (Sigma) were used in West-
ern blots at a dilution 1:1000 and by immunofluorescence at
1:50 or 1:100, respectively. 53BP1 was detected by immunoflu-
orescence with either polyclonal 53BP1 (H-300) (Santa Cruz
Biotechnology) or monoclonal anti-53BP1 from Upstate at a
1:50 dilution (no differences in focus number or sizewere found
between the two antibodies detecting 53BP1). Antibodies
against phospho-53BP1(Ser-25/Ser-29), phospho-p53(Thr-
18), phospho-CHK2(Thr-68), CHK2, phospho-CHK1(Ser-
317), CHK1, and phospho-Rb(Ser-807/Ser-811) were fromCell
Signaling Technology. Antibodies for phospho-ATRIP(Ser-68/
Ser-72), ATRIP, phospho-DNA-PK(Ser-2056), and DNA-PK
were from Abcam (Cambridge, UK). Antibodies against p53
(DO-1 and Pab-1801 clones), phospho-p53(Ser-15), p27, and
cyclin D1 were purchased from Santa Cruz Biotechnology.
Antibodies to phospho-ATM(Ser-1981) and ATM were from
Calbiochem. Anti-phosphohistone H2AX(Ser-139) was de-
tected with monoclonal antibody JBW301 clone (Millipore).
MDC1was detectedwith a rabbit polyclonal antibody (Abcam).
Other antibodies used were anti--actin (Sigma), anti-GST
(Santa Cruz Biotechnology), anti-HA (Covance), and anti-
FLAG (Sigma). The secondary antibodies used for Western
blots, anti-(mouse-HRP) and anti-(rabbit-HRP) were from GE
Healthcare. Bands were visualized with an ECL kit (GE Health-
care) followed by exposure to x-ray film (Fujifilm). When indi-
cated, quantification of bands intensity was performed with
Quantity One software (Bio-Rad). The secondary antibodies
used for immunofluorescences were FluoroLinkCy2 anti-
mouse, FluoroLinkCy2 anti-rabbit, FluoroLinkCy3 anti-
mouse, and FluoroLinkCy3 anti-rabbit from GE Healthcare.
DNA Damage—Cells were irradiated with doses ranging
from 2 to 10 Gy using a Gammacell 1000 Elite irradiator with a
137Cs source. Doxorubicin was used at 1 M, etoposide was
used at 50 M, and hydroxyurea was used at 2 mM. DNA dam-
age induced by UV-C light was performed with a Stratalinker
(Stratagene). The actual UV dose delivered was determined by
direct measurement with a radiometer (Spectroline XS-254
nm-UVC, Spectronics Corp., Westbury, NY).
Immunofluorescence Confocal Microscopy and Analysis—Cells
were seeded on cover slides, and forHEK293Tcells, cover slides
were treated with 0.01% polylysine to improve its adherence to
the glass. Cells were washed in cold PBS and fixed with 3%
paraformaldehyde in PBS for 30 min at room temperature.
After fixation, cells were washed with 0.2 M glycine to block the
remaining aldehyde groups. Cells were permeabilized with
0.2% Triton X-100 solution in PBS for 30min and blocked with
1% BSA in PBS for 30 min at room temperature. For the simul-
taneous detection of two proteins, the incubations with pri-
mary antibodies were performed sequentially. Each antibody
was diluted in blocking buffer and incubated for 1 h at room
temperature. Following antibody incubations, cells were
washed three times with PBS for 5 min. Secondary antibodies
labeled with Cy2 or Cy3 were diluted in blocking buffer, and
incubation was performed for 1 h at room temperature. Finally,
nuclei were stained with DAPI (4,6-diamidine-2-fenilindol),
diluted in PBS, and incubated for 10 min at room temperature.
Cells were washed three times for 5 min in PBS. The final wash
was in distilled water. Coverslips were mounted on a slide with
Mowiol 4-88 (Calbiochem). Subcellular localization was deter-
mined by confocal microscopy using a Leica TCS SP5 DMI-
6000B confocal microscope using the following lasers: argon
(488 nm), diode-pumped solid state (561 nm), and UV diode
(405 nm). Fluorescent images were captured with a 63.0 lens
zoomed in 1.5–3with a 1024 1024 frame and 600-Hz scan-
ning speed. The following scanner settings were maintained
constant throughout all samples examined: pinhole (95.6 m),
laser intensity, and photomultiplier gain and offset. Images
were analyzed with Leica LAS AF and NIH ImageJ software.
Immunoprecipitations—Immunoprecipitations were per-
formed using 1.5mg of total cell extracts. Cells were lysed in the
indicated lysis buffer (see below). To avoid nonspecific interac-
tions, cell extractswere preincubatedwith 30l ofGammaBind
Plus Sepharose beads (GE Healthcare) equilibrated in the same
buffer as the extracts and incubated for 1 h at 4 °C with orbital
rotation. The beds were removed by centrifugation, and the
extract was incubated with the specific antibody indicated in
the experiment for 3 h. Afterward, 40 l of GammaBind Plus
Sepharose beads, which had been previously blocked with
seralbumin (BSA), were added and incubated for 2–3 h or over-
night at 4 °C with rotation. Next the resin was washed several
times in lysis buffer before processing for gel loading. The
immunoprecipitate was fractionated by SDS-PAGE, and the gel
was transferred to a PDVF membrane (Immobilon-P, Milli-
pore) for Western blot analysis (41, 42). For kinase assays,
immunoprecipitated proteins were washed several times in the
appropriate kinase buffer and then used in kinase assays. Lysis
buffer used for VRK1 immunoprecipitation was composed of
50 mM Tris, pH 8.0, 1% Triton X-100, 200 mM NaCl, 5 mM
EDTA, 1 mM NaF, and 1 mM sodium orthovanadate plus pro-
tease inhibitors (25). Lysis buffer for 53BP1 immunoprecipita-
tion (NETN buffer; Ref. 33) contained 20mMTris-HCl, pH 8.0,
0.5% Nonidet P-40, 300 mMNaCl, 1 mM EDTA, 1 mMNaF, and
1 mM sodium orthovanadate plus protease inhibitors. Lysis
buffer for ATM immunoprecipitation (43) contained 50 mM
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Tris, pH7.5, 150mMNaCl, 1%Tween 20, 0.5%Nonidet P-40, 50
mMNaF, and 1 mM sodium orthovanadate plus protease inhib-
itors. Lysis buffer for ATR immunoprecipitation (35) contained
25 mM Hepes, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 50 mM -glycerophosphate, 0.5% Triton X-100, 1 mM
NaF, and 1 mM sodium orthovanadate plus protease inhibitors.
GST Pulldown Assays—GST pulldown experiments were
performed by incubating 3 g of GST-tagged 53BP1 fragments
with 0.1g of purified VRK1-His in 250l of binding buffer (50
mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM
EDTA, and 2 mM DTT) for 2 h at 4 °C. GST-tagged 53BP1
fragments along with interacting VRK1 were precipitated by
adding glutathione-Sepharose beads. Beads were washed five
times with binding buffer, and proteins were resolved by SDS-
PAGE. Interacting VRK1 was detected with anti-VRK1 mono-
clonal antibody (1F6) (39), and GST-53BP1 fragments were
detected with anti-GST antibody.
Flow Cytometry Analysis—Cellular DNA content and cell
cycle profiles were determined by flow cytometry in a FACSC-
alibur flow cytometer (BD Biosciences). Data acquisition was
carried out with the Cell Quest program (BD Biosciences), and
data were analyzed with Paint-a-Gate and ModFit programs
(BD Biosciences).
RESULTS
Activation of VRK1 by DNADamage in Resting Cells—VRK1
has been indirectly linked to the DDR as a p53 kinase (16–18,
22). Because VRK1 phosphorylates p53 at Thr-18 (16–18) and
is also implicated in some DDR (18, 22), we hypothesized that
VRK1 might also be activated in early steps of cellular DDR. In
this work, we determined whether VRK1 can be regulated by
DNA damage as an indication of response to altered chromatin
structure and determined its consequences on the response to
DSBs detected by the formation of 53BP1 foci, a process that is
independent of p53 (9). In the first place, we sought to deter-
mine whether arresting cells by serum deprivation would affect
the activity of VRK1. In the breast human adenocarcinoma
MCF7 cell line, we observed that serum deprivation led to loss
of VRK1 kinase activity, which was restored upon readdition of
serum (Fig. 1A). Next, we determined whether cells arrested
and treated with different physical and chemical agents that
cause DSBs were able to induce VRK1 activation (Fig. 1B). Cell
treatment with IR, the DNA intercalator doxorubicin, and the
topoisomerase inhibitor etoposide C caused an 8–12-fold
increase in VRK1 kinase activity (Fig. 1B). The activity of VRK1
is known to be insensitive to caffeine (17), an inhibitor of PI3K-
related kinases, such as ATM and ATR, and to KU55933, an
ATM-specific inhibitor (44). The arrested status of the cell
cycle was confirmed by a reduction in phospho-Rb and cyclin
D1 and an increase in p27 inhibitor levels (Fig. 1C). The imme-
diate activation of the kinase activity of VRK1 by IR suggested
that its role is likely to be that of a sensor protein.
IR Activates VRK1 and Induces Its Association to and Phos-
phorylation of 53BP1—The 53BP1 protein plays an important
early role as a scaffold protein in DDR and is required for the
assembly of DNA repair foci (9), activation of ATM (45), and
downstream regulation of cell cycle checkpoints (46). We
hypothesized that 53BP1 is also a phosphorylation substrate of
VRK1. To test this possibility, we transfectedHEK293T cells (9)
with full-length 53BP1 protein, immunoprecipitated 53BP1,
and used it as substrate in a VRK1 in vitro kinase assay. Results
showed that 53BP1 was phosphorylated by VRK1 (Fig. 2A). To
identify the specific target region of this phosphorylation, sev-
eral GST-53BP1 fusion proteins spanning the complete
sequence of 53BP1 (33) were used as substrates in the VRK1
kinase assay. VRK1 strongly phosphorylated the N-terminal
region of 53BP1 (residues 1–346) and more weakly phosphor-
ylated the 339–671 and 628–962 regions (Fig. 2B). To further
confirm that VRK1 phosphorylates 53BP1, serum-starved
FIGURE 1. VRK1 kinase activation in response to DNA damage. A, effect of serum withdrawal on the activity of VRK1. Endogenous VRK1 was immunopre-
cipitated fromMCF7 cells either growing in 10%FBS (lane 1), serum-starved for 48h (lane 2), or serum-starved for 48h followedby15h in 10%FBS (lane 3). VRK1
activity was assayed in vitro for autophosphorylation and phosphorylation of GST-p53(1–85) fragment. B, kinase activity of endogenous VRK1 in response to
DSBs. MCF7 cells were serum-starved and then treated with 2 Gy of ionizing radiation, 1 M doxorubicin, or 50 M etoposide. Endogenous VRK1 protein was
immunoprecipitated and used in an in vitro kinase assay detecting its autophosphorylation and phosphorylation of GST-p53(1–85). C, detection of cell cycle
markers byWestern blot.MCF7 cellswere grown in the presence of serum, serum-starved for 48 h, or serum-starved for 48 h followedby 15h in serum. Extracts
were blotted for phospho-Rb, cyclin D1, p27, VRK1, and actin. IP, immunoprecipitation; IB, immunoblot.
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MCF7 andA549 cells were irradiatedwith 3Gy, and 30min later,
the endogenous VRK1was immunoprecipitated and tested for its
kinase activity with the N-terminal fragment of 53BP1 (residues
1–346) as a substrate. Results showed that endogenous VRK1
phosphorylated 53BP1, and this phosphorylation was enhanced
after the activation of VRK1 by  radiation in both cell lines (Fig.
2C). Finallywe identified theresiduephosphorylated in53BP1.For
this assay, we used theN-terminal (1–346) 53BP1 region as a sub-
strate of VRK1 or ATM, and we detected the phosphorylation of
53BP1at Ser-25/29with aphosphospecific antibody. Significantly,
both kinases independently phosphorylated these residues (Fig.
2D), indicating that the 53BP1 protein is targeted by both kinases.
Intriguingly, both kinases produce a similar phosphorylation pat-
tern on 53BP1 (33).
FIGURE 2.Phosphorylationof 53BP1byVRK1and IR-induced interactionofVRK1with 53BP1.A, full-length 53BP1-HAor empty vectorwas transfected in
293T cells and immunoprecipitated with anti-HA antibody. Immunoprecipitates were used as a substrate of GST-VRK1 in an in vitro kinase assay (25). B,
GST-53BP1 fragments encoding different regions of 53BP1 as indicated were tested for phosphorylation by His-VRK1 in an in vitro kinase assay. The gel was
exposed to x-ray films to detect phosphorylated proteins. C, starved MCF7 (left) or A549 (right) cells were left unirradiated or exposed to 3 Gy of  rays.
Endogenous VRK1was immunoprecipitated 30min after irradiation and assayed for autophosphorylation or phosphorylation of GST-53BP1(1–346) fragment
in a kinase assay. Ig represents an immunoprecipitation with a nonspecific antibody (anti-HA). D, specific phosphorylation of 53BP1. In vitro phosphorylation
of GST-53BP1(1–346) fragment was assayed either with GST-VRK1 (bacterially expressed) or ATM-HA (prepared by immunoprecipitation from 293T cells). The
phosphorylation of 53BP1 was determined by Western blot with an anti-Ser-25/29 phosphospecific antibody (Cell Signaling Technology). E, induction of
endogenous VRK1 and 53BP1 protein interaction by ionizing radiation. A549 cells were either left untreated or irradiatedwith 3 Gy. After 30min, endogenous
53BP1 was immunoprecipitated using a polyclonal anti-53BP1 antibody. Control immunoprecipitations were performed with a polyclonal antibody (anti-
FLAG). Endogenous VRK1 protein was only detected in the 53BP1 immunoprecipitate from irradiated cells. F, mapping the interaction region of 53BP1 with
VRK1. SixGST-53BP1 fragments spanning the full-length 53BP1protein as indicatedwere incubatedwithpurifiedVRK1-His and subjected toGSTpulldown (25,
74). Proteins were separated by SDS-PAGE followed by immunoblotting with anti-VRK1 antibody (1F6 mAb). IP, immunoprecipitation; IB, immunoblot.
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Because phosphorylation requires at least a transient inter-
action between VRK1 and 53BP1, we also determined whether
this interaction could be induced by ionizing radiation. We
immunoprecipitated endogenous 53BP1 protein from non-ir-
radiated or irradiated A549 cells, and we determined the pres-
ence of VRK1. In irradiated cells, we could observe endogenous
VRK1 in the 53BP1 immunoprecipitate forming a complexwith
endogenous 53BP1, confirming that this interaction is induci-
ble in vivo by IR (Fig. 2E). Because 53BP1 is a large protein with
several domains, to assess the specific region of interactionwith
VRK1, we performed pulldown assays with different GST-
53BP1 constructs spanning its complete length. Western blot
confirmed that VRK1 interacts with the 53BP1 region compris-
ing residues 956–1354 (Fig. 2F).
Next we determined the sequential activation of VRK1 and
53BP1 focus formation in response to IR by confocal micros-
copy. The conformational activation of VRK1 reached its peak
at 5 min after IR, whereas 53BP1 focus formation reached its
maximum between 15 and 30 min after IR in A549 cells (sup-
plemental Fig. S1). Thus, VRK1 activation precedes 53BP1
focus formation.
Loss of VRK1 Results in Defective Formation of 53BP1 Foci in
Response to IR—The 53BP1 interaction and its phosphorylation
by VRK1 induced by IR suggested that VRK1 might be neces-
sary for the formation of 53BP1 foci in the DSB response (9, 10,
47). Therefore, we determined whether VRK1 knockdown (17,
23) would affect focus formation in DDR by detecting the
assembly of 53BP1 into IR-induced foci in A549 cells (9). VRK1
knockdown causes entry of the cells in G0 even in the presence
of serum, which cannot revert this cell cycle arrest (23) because
VRK1 is required for cyclin D1 gene expression (48). Notably,
following irradiation, we observed a decrease in 53BP1 focus
formation in siVRK1-02- (Fig. 3A and supplemental Fig. S2A)
or siVRK1-01-treated cells (supplemental Fig. S2B) but not in
control cells (not transfected), starved cells, and siControl. The
formation of foci in starved cells permitted us to rule out the
stop in cell cycle as the cause of the effect. Although VRK1
shows a pan-nuclear localization, 53BP1 staining overlaps with
VRK1 signal in IR-induced foci (Fig. 3A and supplemental Fig.
S2B), which is likely to represent a minor VRK1 subpopulation
of the abundant nuclearVRK1protein.Quantification of 53BP1
foci showed that in irradiated cells with siVRK1-02 or
siVRK1-01 knockdown there was a significant reduction in
both number and size of 53BP1 foci (Fig. 3A and supplemental
Fig. S2B), which suggests that VRK1 is necessary for proper
assembly of 53BP1 foci in response to ionizing radiation. A
similar effect was also detected in HEK293T (supplemental Fig.
S3A), H1299 (p53/) (supplemental Fig. S3B), and MCF7
cells (supplemental Fig. S3C), indicating that the effect of VRK1
on 53BP1 focus formation is independent of cell type and p53
status.
Next we performed a rescue of the defective 53BP1 focus
phenotype.We transfectedA549 cells inwhich the endogenous
VRK1 was previously knocked down with siVRK1-01 with a
plasmid expressing a mutated form of VRK1 containing silent
nucleotide changes in three codons (Arg-391, Arg-393, and
Val-394), whichmake it insensitive to siRNA-01 (supplemental
Fig. S4). We treated cells with 3 Gy and determined the forma-
tion of 53BP1 foci. Interestingly, transfection of cells with the
resistant VRK1 mutant restored both the number and size of
53BP1 foci (Fig. 3, B and C) to control levels, whereas in cells
that did not take up the mutant, the formation of foci was defi-
cient, and the phenotype of siVRK1was clearlymanifested (Fig.
3B). This observation confirmed that VRK1 is a necessary step
for the correct formation of 53BP1 foci.
VRK1 Is Activated by IR and Induces 53BP1 Foci inATM/
Cells—The response to double strand breaks is mainly medi-
ated by the ATM-CHK2 pathway (49).Therefore, we hypothe-
sized that if VRK1 has an effect on 53BP1 focus formation that
is independent of ATM VRK1 knockdown should affect the
formation of these foci in ATM-deficient cells. To test this, we
knocked down VRK1 in HT144 and GM9607 cells and deter-
mined its effect on 53BP1 focus formation in response to IR.
These two ATM-deficient cell lines have a high level of back-
ground 53BP1 foci, which are increased by IR (Fig. 4A and sup-
plemental Fig. S5). In cells in which VRK1 was knocked down,
wewere able to identify a significant reduction in size and num-
ber of 53BP1 foci (p  0.001). This result confirms the ATM-
independent role of VRK1 in DDR. Next, we determined the
activation of VRK1 kinase activity in response to IR in ATM-
deficient HT144 cells through autophosphorylation and 53BP1
phosphorylation assays. We observed an increase of phos-
phorylation in both proteins despite the lack of ATM (Fig. 4B).
These data suggested that activation of VRK1 and phosphoryl-
ation of 53BP1 are mediated independently of ATM in serum-
starved HT144 cells. We also observed that the specific phos-
phorylation of p53 at Thr-18 was induced by IR in these cells,
but it was lost if VRK1 was knocked down (Fig. 4C). Thus, we
can conclude that this Thr-18 phosphorylation of p53 is VRK1-
dependent and ATM-independent. These results indicated
that VRK1 represents an alternative DNA damage response
component independent of ATM and upstream of p53 and
53BP1 in DDR.
VRK1 Elimination Prevents Activating Phosphorylations of
ATM, CHK2, and DNA-PK—Next we determined whether
VRK1 could also affect the efficient activation of ATM-CHK2
in the DDR signaling. We observed that irradiation of A549
cells with  rays induced activation of ATM and CHK2 as
detected by specific phosphorylation of ATM at Ser-1981 (43)
and CHK2 at Thr-68 (50, 51). However, these specific phos-
phorylation events were lost upon knockdown of VRK1 with a
reduction greater than 90% when VRK1 was knocked down as
detected by the changes in the ratios between phosphorylated
and unphosphorylated proteins (Fig. 5A). Thus, VRK1 is also
upstream of ATM-CHK2. In these cells, p53 accumulated in
response to IR as expected. We observed similar results when
we tested the effect of VRK1 knockdown on the activating auto-
phosphorylation of DNA-PK at Ser-2056; there was a reduction
in phosphorylation of 90% (52) (Fig. 5B).
Although ATR plays a secondary role in DDR (53), we also
wanted to determine whether VRK1 knockdown had any effect
on ATR activation. We observed that the elimination of VRK1
did not affect the phosphorylation of ATRIP at Ser-68/72 (Fig.
5C), a direct target of ATR, although 53BP1 focus formation
was impaired under these conditions (Fig. 3A and supplemental
Fig. S2). Therefore, we conclude that the ATR signal is not
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FIGURE 3. Knockdown of VRK1 prevents 53BP1 ionizing radiation-induced focus formation. A, A549 cells were transfected with siRNA oligos targeting
VRK1 (siVRK1-02), control oligos (siControl), not transfected (NT), or not transfectedand serum-starved (0.2%FBS). Forty-eighthours after transfection, cellswere
either untreated or treated with 3 Gy. 53BP1 focus formation was determined 30 min after irradiation by confocal microscopy (9). VRK1 was detected with a
polyclonal antibody, and 53BP1 was detected with a monoclonal antibody. VRK1 knockdown efficiency was checked by Western blot (top right) (18, 23).
Quantification of the number of 53BP1 foci per cell was performedwith ImageJ software. Around 100 cells for each condition were analyzed. Means, S.D., and
numberof cells analyzedare shown in thegraph (bottom right). A representative fieldwith several cells to show thephenotypeand the cell cycleprofile of these
cells are shown in supplemental Fig. S2A. A different siRNA induced the same phenotype (supplemental Fig. S2B). ***, p 0.001. NT, non-transfected control;
siC, siControl; siV, siVRK1-02. B, rescue of defective 53BP1 focus formation by an siRNA-resistant VRK1. A549 cells were transfected with siVRK1-01 to knock
down endogenous VRK1 or with siControl. After 36 h, cells were retransfected with 2g of plasmid HA-VRK1(R391/R393/V394) with three silent substitutions
that render the cDNA insensitive to si-VRK1-01. Thirty-six hours after retransfection, cells were irradiated with 3 Gy and left to recover for 30 min. Cells were
immunostainedwith anti-HAmonoclonal antibody to identify cells expressing exogenous VRK1. 53BP1 foci were visualized by stainingwith 53BP1 polyclonal
antibody. The efficiency of endogenous VRK1 silencing and expression of siRNA-resistant VRK1 was determined by Western blot (supplemental Fig. S5). C,
quantificationof thenumber of 53BP1 foci in the rescue experiment. NIH ImageJ softwarewasused for counting53BP1 foci.Meansof thenumber of 53BP1 foci
per cell and S.D. are represented in the graph. The number of analyzed cells is indicated below. ***, p 0.001. siV1-1, siVRK1-01; IB, immunoblot. Error bars
represent the standard deviation.
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affected by VRK1 in this DSB response and is not implicated in
the immediate formation of 53BP1 foci, although itmight play a
role at later points during the evolution in time of DDR com-
plexes (54). Overall, these results indicate that VRK1, in addi-
tion to its direct effect on IR-induced focus assembly, is a novel
upstream component in the DDR mediated by the ATM and
DNA-PK, but not ATR, signaling pathways. Finally, to rule out
the possibility that VRK1, ATM, ATR, and CHK2 were sub-
strates of each other, we studied their in vitro combinations
using kinase-dead proteins as targets and p53 as a positive con-
trol (supplemental Fig. S6, A–C). None of these active kinases
phosphorylated kinase-dead VRK1, nor were their inactive
forms phosphorylated by VRK1. These results indicated that
these kinases are not directly interacting or phosphorylating
each other, but whether they might be forming part of a larger
complex cannot be ruled out.
Effect of VRK1 Knockdown on the Formation of H2AX and
MDC1 Foci Induced by IR—The previous results suggested that
the effect of VRK1 is an early event in the response to DDR that
is upstream of ATM. To confirm this role, the effect of VRK1
knockdown on the formation of H2AX, that is the initial event
(55), and onMDC1 foci, which are dependent onATM (56, 57),
was determined. MDC1 is required for recruitment of 53BP1
(58). The elimination of VRK1 in A549 cells resulted in defec-
tive formation of histone H2AX (Fig. 6A), consistent with an
early role for VRK1 in DDR. But on the other hand, knockdown
of VRK1 had no effect on MDC1 foci (Fig. 6B), suggesting that
there are alternative routes of focus formation.
DISCUSSION
The initial response to DNA damage is likely to be the con-
sequence of an altered chromatin structure. At the site of the
DNA damage, specific detection of signaling mechanisms need
to be activated according to the type of damage to achieve a
proper repair. Until now, most of the studies on DDR have
centered on mechanisms operating in the context of cell cycle
regulation and its checkpoints to maintain genome integrity.
One important observation is that most of an organism’s cells
FIGURE 4. Defective 53BP1 foci in ATM/ cell lines by loss of VRK1. A, HT144 and GM9607 cells were transfected with siVRK1-02 or siControl or not
transfected (NT). After 72 h, cells were either untreated or exposed to 3 Gy of IR and allowed to recover for 30 min. Cells were immunostained with 53BP1
polyclonal antibody. The quantification of the number of 53BP1 foci per cell in each condition is shown in the graphs. Means and S.D. are represented. The
number of cells analyzed is indicatedbelow. Images showing several cells andVRK1protein levels detectedbyWestern blot are shown in supplemental Fig. S5.
***, p 0.001. B, activation of VRK1 in response to IR in HT144 cells. Endogenous VRK1was immunoprecipitated from non-irradiated or 3-Gy irradiated HT144
starved-cells. This immunoprecipitatewas used to assess VRK1 autophosphorylation and phosphorylation of GST-53BP1(1–346) in an in vitro kinase assay. Ig is
a negative controlwith anonspecific antibody (anti-HA).C, phosphorylationof p53 at Thr-18 is dependent onVRK1 inHT144 cells. HT144 cellswere transfected
with siVRK1-02or siControl or not transfected (NT). After 24h, cellswere serum-starved for 40h and then irradiatedwith 10Gyof IR or left untreated. Cell lysates
wereprepared1hafter irradiation, andWesternblotswereperformedwithantibodies toVRK1 (1B5), phospho-Thr-18-p53, p53, andactin.Quantificationof the
levels of phospho-Thr-18-p53 and total p53 is shown in the graph. IP, immunoprecipitation; IB, immunoblot. Error bars represent the standard deviation.
VRK1 Is Required for Assembly of 53BP1 Foci
23764 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 28•JULY 6, 2012
 at IN
STITU
TO
 D
E BIO
LO
G
IA
 FU
N
CIO
N
A
L Y
 G
EN
O
M
ICA
 CSIC on July 1, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
are not dividing and that induced DNA damage occurs most
frequently in resting cells. This fact supports the survival
advantage for additional elements in DDR that might have a
redundant role with other already knownmechanisms and that
are uncoupled from cell cycle regulation. In this work, we have
identified that VRK1 is a kinase whose activity is enhanced in
response to DNA damage and is a key component involved in
channeling a specific response. The induction of VRK1 associ-
ation with 53BP1 upon IR is consistent with it being both
upstream and downstream of IR-induced focus formation.
However, because the elimination of VRK1 results in defective
53BP1 focus formation, we can conclude that it has an
upstream role in the process, although it may be acting in con-
cert with other known pathways. It is important to note that
VRK1 plays a role in defective focus formation even in the
absence of ATM. 53BP1 foci are formed even in the absence of
ATM, which is a transducer protein in DDR. Furthermore,
VRK1 knockdown results in loss of activation of several path-
ways, including ATM-CHK2 and DNA-PK, as detected by the
loss of their specific activating phosphorylation marks. This
observation has two clear implications. First, VRK1 is upstream
of 53BP1 foci and at the same time is a common component of
sensor pathways. Second, the specificity of the response is
determined by downstream components in the process. The
position of VRK1 upstream of 53BP1 is also consistent with the
observation of 53BP1 as an upstream step in ATM activation
(45). Furthermore, the observation that VRK1 affects IR-in-
duced focus formation in ATM-defective cells suggests that the
VRK1-mediated response is an independent pathway whose
activity is required for ATM and DNA-PK, but not ATR, acti-
vation (59). These results suggest that VRK1 represents an
alternative and perhaps partially redundant pathway of DDR
(8), which might be particularly relevant in the context of
arrested cells, such as stem cells (60).
The significance of the 53BP1 phosphorylation at residue
Ser-25/29 by ATM or VRK1 is that it likely affects its interac-
tion with other proteins in its less characterized N-terminal
FIGURE 5. VRK1 is an upstream element in DDR. A, effect of VRK1 knock-
down on the activation of ATM and CHK2 induced by IR. A549 cells were
transfected with siVRK1-02 or siControl oligos or not transfected (NT). After
48h, cellswere treatedwith10Gyor left untreated. Cell lysateswereprepared
1 h later and immunoblotted for VRK1 expression (1B5 antibody) and for
specific phosphorylation of CHK2 in Thr-68 (anti-phospho-Thr-68-CHK2) and
p53at Ser-15 (anti-phospho-Ser-15-p53). ATMwas immunoprecipitated from
cell lysates with anti-ATM antibody and immunoblotted for specific phos-
phorylation at Ser-1981. The ratio of phospho-CHK2 (P-CHK2)/CHK2 and
phospho-ATM (P-ATM)/ATM are shown below the corresponding gels.
B, effect of VRK1 knockdown on the activation of DNA-PK. Cell lysates were
immunoblotted with antibodies to phospho-Ser-2056-DNA-PK, DNA-PK,
VRK1 (1B5 antibody), and actin. The ratio of phospho-DNA-PK (P-DNA-PK)/
DNA-PK is shown below the gel. C, effect of VRK1 knockdown on ATR-depen-
dent phosphorylation of ATRIP. Immunoblots were performed with anti-
bodies to phospho-Ser-68/Ser-72-ATRIP, ATRIP, VRK1 (1B5 antibody), and
actin. IP, immunoprecipitation; IB, immunoblot; siCt, siControl; siV1, siVRK1.
FIGURE 6. Effect of VRK1 knockdown on the formation of histone H2AX
(A) and MDC1 (B) foci in response to IR. A549 cells were transfected with
siControl or siVRK1-02 and treated with 3 Gy as indicated under “Experimen-
tal Procedures.” The formation of H2AX foci was determinedwithmonoclo-
nal antibody JBW301, and the formation ofMDC1 foci was determinedwith a
polyclonal antibody by confocal microscopy. VRK1was detectedwithmono-
clonal antibody 1B5, which detects a conformational change in its C-terminal
region. NT, not transfected.
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region. This phosphorylation does not affect DNA repair (61),
but it is necessary for 53BP1 binding to the BRCT domains of
hPTIP (62, 63), and its abrogation results in reduced CHK2
activation (63). This is consistent with the effect of VRK1 loss
onCHK2 activation (Fig. 4D), althoughmutation of this residue
does not affect the ability of the cell to repair damaged DNA
(61), suggesting that there are alternative response pathways.
VRK1 interacts with the central region, residues 956–1354, of
53BP1, which is outside the Tudor and BRCT domains that
induce 53BP1 foci and interact with p53, respectively (45). This
53BP1 region overlaps with a putative binding site for Plk1 (64).
VRK1 probably plays different roles during DDR. Initially it is
required for the recruitment or assembly of 53BP1 foci, but
following its incorporation into these foci, VRK1 probably par-
ticipates in the regulation or incorporation of additional com-
ponents in the response pathway that remain to be identified
and that are temporally and spatially regulated.
The evidence indicates that VRK1 is likely to play more than
one role in DDR. First, it is clearly an early component as indi-
cated by the immediate activation of its kinase activity follow-
ing irradiation and preceding formation of H2AX and 53BP1
foci. But the DDR response is dynamic, and roles change with
time from damage-sensing to damage repair, and thus down-
stream signaling might be affected as is the case for phos-
phorylation of p53, ATM,CHK2, andDNA-PK, all of which are
reduced by loss ofVRK1.TargetingVRK1with inhibitorsmight
eventually be a potential aim in chemotherapy, althoughmech-
anistically inhibitors might have different roles. In proliferating
tumor cells, inhibitors aremost likely to function by the effect of
VRK1 loss on the cell cycle (23). However, in non-proliferating
tumor cells, the effect might be indirect and a consequence of
allowing the accumulation of additional genetic damage in rest-
ing tumor cells so that when reentering the cell cycle they will
be more prone to die because of the accumulated damage.
VRK1 is not sensitive to kinase inhibitors (44) due to the struc-
ture of its kinase domain (65, 66) and low promiscuity with
regard to inhibitors (67).
The role ofVRK1 inDDR suggests that itmay also participate
in normal processes in whichDNA recombination occurs, such
asmeiosis. Thus, VRK1 knock-outmice have defects inmeiosis
resulting in male and female sterility (68–70) in addition to
defects in cell proliferation (71). Its D. melanogaster ortholog,
NHK-1, also affects meiotic recombination (72). Recently a
recessivemutation inVRK1, R385X,manifested a complex syn-
drome with a pontocerebellar hypoplasia, ataxia, and muscular
atrophy (73). Although the pathogenic role of VRK1 in this
clinical report is not clear, it is interesting to note that patients
with mutations in other kinases, like ATM and ATR, also pres-
ent motor coordination problems and ataxia (1). Defects in
DDR pathways are also associated with spinocerebellar ataxias
(7). VRK1, like NHK-1, is a nucleosomal histone kinase and
thus is a likely player in all processes implicated in chromatin
alterations, normal or pathological. The identification of VRK1
as a novel upstream element in DDR opens up new possibilities
to understand the mechanisms regulating the specificity of cel-
lular protection in the contexts of DNA damage and
recombination.
VRK1, a late appearing nucleosomal kinase in evolution, is
likely to play a coordinating role among different signaling
pathways that have to be tightly organized and coordinated in
time and space in response to DNA damage. Future study into
these processes and their pathology will clarify how these mas-
ter pathways of sensing and responding to DNA damage
converge.
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Figure S1. Time course of VRK1 conformational chane and 53BP1 foci induced by irradiation. A. A549 cells
were irradiated with 3Gy and the change in reactivity of VRK1 can be detected with monoclonal antibody 1B5 that
detects its C-terminal change in conformation. 53BP1 foci was determined with a specific antibody. Maximun
change in VRK1 reactivity was detected at five minutes. The peak of 53BP1 foci was reached at thirty minutes B.
lack of effect of irradiation on endogenous VRK1 protein level detected in a western blot. C. Graphical
representation of the quantification of 53BP1 foci per cell induced by irradiation. Confocal microscopy
immunofluorescence and immonoblots were performed as reported in the methods section.
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Figure S2. Knock-down of VRK1 prevents 53BP1 irradiation-induced foci. A. Left. Representative field with
several cells to show the phenotype corresponding to figure 3A. Right. Cell cycle profile of these cells is shown.
siVRK1-02 and 0.2% FBS 48h produce the same effect on cell cycle, but only siVRK1 affects 53BP1 foci formation
in response to IR. B. Knock-down of VRK1 with a different siRNA produces the same defective 53BP1 foci
phenotype. A549 cells were transfected with siVRK1-01 oligos targeting VRK1, siControl oligos or not transfected
(NT). 48 hours later cells were treated with 3 Gy and 53BP1 foci formation was determined 30 minutes after
irradiation by confocal microscopy. VRK1 was detected with a polyclonal antibody (Sigma) and cy3-conjugated
secondary antibody. 53BP1 was detected with a monoclonal antibody (Upstate) and cy2-conjugated secondary
antibody. In parallel, cell lysates were made and western blot performed to determine VRK1 (1B5 antibody) and
actin protein levels. si-VRK1-01 treatment produces a significant reduction on VRK1 protein levels. ImageJ software
(NIH) was used for 53BP1 foci counting. Average number of 53BP1 foci per cell and standard deviation is
represented in the graph. The number of cells analyzed is indicated below. *** p<0.001. NT: not transfected control.
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Figure S3. Knock-down of VRK1 impairs 53BP1 irradiation-induced foci formation in HEK-293T,
H1299 (p53 -/-) and MCF7 cells. HEK-293T, H1299 and MCF7 cells were transfected with siRNA oligos
targeting VRK1 (siVRK1-02), control oligos (siControl) or not transfected (NT). 72 hours later, cells were
either untreated or exposed to 3-Gy IR and allowed to recover for 30 minutes. Cells were fixed for
immunofluorescence or lysed for Western Blot. A, B, C. Immunofluorescences showing 53BP1 ionizing
radiation-induced foci. HEK-293T (A), H1299 (B) and MCF7 (C) cells were immunostained with 53BP1
polyclonal antibody H-300 (Santa Cruz) at dilution 1:50 and cy2-conjugated secondary antibody, and with
VRK11B5 monoclonal antibody at dilution 1:50 and cy3-conjugated secondary antibody (not shown). Images
show a representative field and a cellular detail of each cell type. D. VRK1 protein levels. Cell lysates from
the three different cell lines were separated by SDS-PAGE an then immunoblotted with antibodies to VRK1
(1B5) and actin. E, F, G. Each graph represents the number of 53BP1 foci per cell for the corresponding cell
line: HEK-293T (E), H1299 (F) and MCF7 (G). ImageJ software (NIH) was used for 53BP1 foci counting.
Average number of 53BP1 foci per cell and standard deviation is represented in the graphs. The number of
cells analyzed is indicated below. *** p<0.001. NT: not transfected control. siC: siControl. siV1: siVRK1-02
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Figure S4. Phenotype rescue. A. Insensitivity of mutant VRK1(R391/R393/V394)-HA to shVRK1-01.
Plasmid VRK1(R391/R393/V394)-HA has three mutations in the region targeted by RNAi 01 (VRK1
target region: GAAAGAGAGTCCAGAAGTA; mutations marked in bold:
GGAAGAGGGTGCAGAAGTA). A549 cells were transfected with 1 μg of VRK1-HA or
VRK1(R391/R393/V394)-HA plasmids in combination with increasing amounts of sh-VRK1-01
plasmid (pSUPERIOR-VRK1-01). The level of transfected protein was determined with an anti-HA
antibody. B. Efficiency of endogenous VRK1 silencing in rescue experiment. A549 cells were
transfected with siVRK1-01 to knock down endogenous VRK1, or with siControl. 36 hours later cells
were retransfected with 2 μg of plasmid HA-VRK1(R391/R393/V394) or 2 μg of empty vector. 36 hours
after second transfection, cells were irradiated with 3-Gy and left recover for 30 minutes. Cells were
prepared for immunostaining (Fig. 3B) or lysed for Western blotting. Endogenous VRK1 and
overexpressed HA-VRK1(R391/R393/V394) were detected simultaneously in Western Blot with an anti-
VRK1 antobody (Sigma).
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Figure S5. Defective 53BP1 foci in ATM-/- cell lines by loss of VRK1. Left. Representative field
with several cells to show the phenotype corresponding to figure 4A. Right.Western Blots showing
VRK1 protein levels. HT144 and GM9607 cells were transfected with siVRK1-02, siControl or
not transfected (NT). 72 hours later, cells were either untreated or exposed to 3-Gy IR and allowed
to recover for 30 minutes. Cells were fixed for immunofluorescence (left) or lysed for Western
Blot (right). Cell lysates were separated by SDS-PAGE and VRK1 detected with 1B5 monoclonal
antibody.
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Figure S6. VRK1 is neither a kinase nor a substrate of ATM, Chk2 or ATR. A. ATM-HA and ATM-KD-
HA were prepared by transfection and immunoprecipitation from HEK-293T cells. GST-VRK1 wt and kinase
dead GST-VRK1(K179E) were bacterially expressed and purified. GST-p53 fragment (1-85) is a known
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Methods. B. Chk2-FLAG and Chk2-KD-FLAG were prepared by transfection and immunoprecipitation from
HEK-293T cells. GST-VRK1 wt and kinase dead GST-VRK1(K179E) were bacterially expressed and
purified. GST-VRK1(K179E) was thrombin-digested to remove GST moiety. GST-p53 (1-85) was used as
positive control for VRK1 ability to phosphorylate substrates. C. ATR-FLAG and ATR-KD-FLAG were
prepared by transfection and immunoprecipitation from HEK-293T cells. GST-VRK1 wt and kinase dead
GST-VRK1(K179E) were bacterially expressed and purified. GST-p53 (1-85) was used as positive control for
ATR substrate phosphorylation. KD: kinase dead, WT: wild type
GST-VRK1(K179E)    +    +   +   ─   ─
ATM-HA    ─  WT KD WT KD  IP:αHA 
GST-p53 (1-85)    ─   ─   ─   +   +   
32P
GST-p53 (1-85)
GST-VRK1(K179E)
32P
GST-VRK1(K179E)
IB: αGSTGST-p53 (1-85)
IB: αGST
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